Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.
Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic CancerCancer of the Prostate
- Interventions
- Other: 177Lu-PSMA617
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Target Recruit Count
- 201
- Registration Number
- NCT03392428
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Royal North Shore Hospital, Sydney, New South Wales, Australia
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
- Conditions
- Castration-resistant Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 220
- Registration Number
- NCT03356912
- Locations
- 🇮🇹
University Federico II of Naples, Naples, Italy
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
- Conditions
- Prostate Cancer MetastaticMetastasis
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03295565
- Locations
- 🇳🇱
Deventer Ziekenhuis, Deventer, Netherlands
🇳🇱Academisch medisch centrum Maastricht, Maastricht, Netherlands
🇳🇱Haga Ziekenhuis, The Hague, Netherlands
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men with AVPC
- Conditions
- Prostate Cancer AggressivenessProstate Carcinoma
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 119
- Registration Number
- NCT03263650
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2018-04-11
- Target Recruit Count
- 25
- Registration Number
- NCT03257891
- Locations
- 🇮🇹
Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2022-11-18
- Target Recruit Count
- 17
- Registration Number
- NCT03114254
- Locations
- 🇬🇧
Bristol Haematology and Oncology Centre, Horfield Road, Bristol, United Kingdom
🇬🇧Universitty College Hospitals NHS Trust, London, United Kingdom
Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic
- Conditions
- Circulating Tumor CellsChemotherapyProstate CarcinomaCastration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 40
- Registration Number
- NCT03101046
- Locations
- 🇫🇷
ICO-Site René Gauducheau, Saint-Herblain, France
🇫🇷Centre Léon Berard, Lyon, France
🇫🇷CHD Vendée, La Roche-sur-Yon, France
Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
- Conditions
- Circulating Tumor CellMetastatic Prostate Cancer
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 140
- Registration Number
- NCT03050866
- Locations
- 🇳🇱
Franciscus Gasthuis en Vlietland, Rotterdam, Netherlands
🇳🇱Groene Hart Ziekenhuis, Gouda, Netherlands
🇳🇱Maasstad Ziekenhuis, Rotterdam, Netherlands
Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer
- Conditions
- HER2 Negative Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2019-11-13
- Target Recruit Count
- 160
- Registration Number
- NCT03048942
- Locations
- 🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom
🇬🇧Blackpool Victoria Hospital, Blackpool, United Kingdom
🇬🇧Royal United Hospital, Bath, United Kingdom
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2020-02-17
- Target Recruit Count
- 4
- Registration Number
- NCT03043989
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.